Evidence map›Paper›PMID 32115750›Full record

ArticleJournal of cellular biochemistry2020

MeCP2 epigenetically regulates alpha-smooth muscle actin in human lung fibroblasts.

Zheyi Xiang, Qingxian Zhou, Min Hu, Yan Y Sanders

Open access · greenAbstract read
In one paragraph

Article in Journal of cellular biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis.Journal of respiratory biology and translational medicine · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. DNA methylation in pulmonary fibrosis and lung cancer.Expert review of respiratory medicine · 2022
    Review
  9. Macrophage-targeted delivery of siRNA to silenceBioengineering & translational medicine · 2022
    Article
  10. Epigenetic Changes and Functions in Pneumoconiosis.Oxidative medicine and cellular longevity · 2022
    Review
  11. Article
  12. Review
  13. More than a Genetic Code: Epigenetics of Lung Fibrosis.Molecular diagnosis & therapy · 2020
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Zheyi XiangLaboratory of Clinical Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Qingxian ZhouDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Min HuLaboratory of Clinical Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yan Y SandersDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0001-6575-9729
Central South University · CNUniversity of Alabama at Birmingham · US

Funding

Histone H4 Lysine16 Acetylation in Aging and Lung FibrosisR01AG050567 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SANDERS, YAN · 2016 to 2020
$1.5M
NIA NIH HHS R01 AG050567
6 · The paper itself

Abstract

backgroundA critical feature for fibroblasts differentiation into myofibroblasts is the expression of alpha-smooth muscle actin (α-SMA) during the tissue injury and repair process. The epigenetic mechanism, DNA methylation, is involved in regulating α-SMA expression. It is not clear how methyl-CpG-binding protein 2 (MeCP2) interacts with CpG-rich region in α-SMA, and if the CpG methylation status would affect MeCP2 binding and regulation of α-SMA expression.

methodsThe association of MeCP2 with α-SMA CpG rich region were examined by chromatin immunoprecipitation (ChIP) assays in primary fibroblasts from idiopathic pulmonary fibrosis (IPF) and non-IPF control individuals, and in the lung fibroblasts treated with profibrotic cytokine transforming growth factor β1 (TGF-β1). The regulation of α-SMA by MeCP2 was examined by knocking down MeCP2 with small interfering RNA (siRNA). To explore the effects of the DNA methylation status of the CpG rich region on α-SMA expression, the cells were treated with DNA methyltransferase inhibitor, 5'-azacytidine (5'-aza). The expression of α-SMA was examined by Western blot and quantitative polymerase chain reaction, the association with MeCP2 was assessed by ChIP assays, and the methylation status was checked by bisulfate sequencing.

resultsThe human lung fibroblasts with increased α-SMA showed an enriched association of MeCP2, while knockdown MeCP2 by siRNA reduced α-SMA upregulation by TGF-β1. The 5'-Aza-treated cells have decreased α-SMA expression with reduced MeCP2 association. However, bisulfite sequencing revealed that most CpG sites are unmethylated despite the different expression levels of α-SMA after being treated by TGF-β1 or 5'-aza.

conclusionOur data indicate that the methyl-binding protein MeCP2 is critical for α-SMA expression in human lung myofibroblast, and the DNA methylation status at the CpG rich region of α-SMA is not a determinative factor for its inducible expression.

Indexed as

ActinsCell DifferentiationCell TransdifferentiationCpG IslandsCytidine MonophosphateDNA MethylationEpigenesis, GeneticEpigenomicsFibroblastsHumansIdiopathic Pulmonary FibrosisLungMethyl-CpG-Binding Protein 2Muscle, SmoothMyofibroblastsReal-Time Polymerase Chain Reaction5'-azacytidine 5'-monophosphateACTA2 protein, humanActinsCytidine MonophosphateMECP2 protein, humanMethyl-CpG-Binding Protein 2RNA, Small InterferingTGFB1 protein, humanTransforming Growth Factor beta1DNA methylationepigenetic regulationfibrosishuman lung fibroblastIPFMeCP2α-SMA

Identifiers

PMID32115750
PMCPMC7263943
OpenAlexW3010258330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.